Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Strategic Sequencing in Advanced Mycosis Fungoides: Choosing Between Immunomodulatory, HDAC, and Targeted Therapies

June 25th 2025

Panelists discuss how individualized treatment plans must consider disease location, drug access, comorbidities, and newer therapies—such as HDAC inhibitors and immune checkpoint inhibitors— while emphasizing the importance of managing expectations and monitoring adverse effects.

Advanced-Stage Mycosis Fungoides: Navigating Treatment Decisions Amid a Complex Therapeutic Landscape

June 25th 2025

Panelists discuss how treatment goals and selection for advanced-stage cutaneous T-cell lymphoma depend on disease compartmentalization, with therapies like brentuximab vedotin and mogamulizumab being used based on specific disease characteristics and toxicity profiles.

Dr Vose on the Durability of Response to Epcoritamab Monotherapy in DLBCL

June 24th 2025

Julie M. Vose, MD, MBA, discusses the durability of response to epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma.

Five Under 5: Top Oncology Videos for the Week of 6/15

June 22nd 2025

The top 5 OncLive videos of the week cover insights in CLL, multiple myeloma, follicular lymphoma, and extrapulmonary neuroendocrine carcinomas.

The OncFive: Top Oncology Articles for the Week of 6/15

June 21st 2025

Tafasitamab combination gets approval in follicular lymphoma, FDA declines to expand label for talazoparib plus enzalutamide in mCRPC, and more.

Dr Abramson on Findings with Glofitamab, Gemcitabine and Oxaliplatin in R/R DLBCL

June 20th 2025

Jeremy Abramson, MD, discusses the use of glofitamab with gemcitabine and oxaliplatin in patients with relapsed/refractory DLBCL.

Evolving Paradigms in Relapsed DLBCL: Part 2

June 20th 2025

Manali Kamdar, MD, discusses evolving treatment paradigms in diffuse large B-cell lymphoma.

Dr Mehta on the FDA Approval of Tafasitamab Plus Rituximab/Lenalidomide in R/R Follicular Lymphoma

June 18th 2025

Amitkumar Mehta, MD, details the FDA approval of tafasitamab with rituximab and lenalidomide for relapsed/refractory follicular lymphoma.

FDA Approves Tafasitamab Plus Lenalidomide and Rituximab for R/R Follicular Lymphoma

June 18th 2025

The FDA approved tafasitamab-cxix plus lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma.

Monitoring Response in Early-Stage Mycosis Fungoides & Importance of Patient Education

June 18th 2025

Panelists discuss how careful patient monitoring, education, and expectation management are essential in evaluating the effectiveness of skin-directed therapies, emphasizing routine assessments, treatment adherence, and the need for patience due to varying response times.

Other Treatment Strategies in Early-Stage Mycosis Fungoides: TSEBT, Localized Radiotherapy, Phototherapy and Combination Approach

June 18th 2025

Panelists discuss how electron therapy—both spot and total skin electron beam—is used to manage extensive or refractory skin involvement and palliate symptoms in patients with CTCL.

Hematologists Highlight Notable Insights From the 2025 EHA Congress

June 18th 2025

Hematologic oncology experts share the studies they were most excited to see presented at the 2025 EHA Congress.

Bexobrutideg Is Tolerable and Yields High Response Rates in Relapsed/Refractory Waldenström Macroglobulinemia

June 17th 2025

Bexobrutideg was safe and displayed an ORR of 84.2% in relapsed/refractory Waldenström macroglobulinemia.

Axi-Cel, Liso-Cel, and Tisa-Cel Show Comparable Real-World Survival Outcomes in DLBCL

June 17th 2025

Comparable survival outcomes were seen between all 3 FDA-approved CAR T-cell therapies across indications in patients with DLBCL over a 3-year period.

Liso-Cel Yields Durable Responses in R/R Marginal Zone Lymphoma

June 16th 2025

Liso-cel generated deep and durable responses in relapsed/refractory marginal zone lymphoma.

Epcoritamab Plus R-ICE Yields High CR Rates and Improves Transplant Eligibility in R/R DLBCL

June 15th 2025

The majority of transplant-eligible patients with relapsed/refractory DLBCL completed treatment with epcoritamab plus R-ICE and proceeded to ASCT.

Fixed-Duration Epcoritamab Plus Pola-R-CHP Demonstrates Durable Efficacy in First-Line DLBCL

June 15th 2025

Further exploration of epcoritamab plus pola-R-CHP in first-line diffuse large B-cell lymphoma is warranted.

Dr Ku on the Safety Profile of JNJ-90014496 in Relapsed/Refractory LBCL

June 14th 2025

Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, discusses safety and efficacy findings with JNJ-90014496 in relapsed/refractory large B-cell lymphoma.

Real-World Data Confirm Efficacy of Axi-Cel Across Patient-Related Factors in R/R LBCL

June 13th 2025

Although age did not affect real-world ORR or EFS with axi-cel in LBCL, an age of 65 years or older and cardiac comorbidities correlated with shorter OS.

JNJ’4496 Shows Preliminary Efficacy and Safety in Relapsed/Refractory LBCL

June 13th 2025

JNJ’4496 demonstrated an ORR of 100% in patients with relapsed or refractory large B-cell lymphoma who received 1 prior line of treatment.